Drug Database
Back to search

Belgium· BE-AMP-SAM546773-00

Inbrija 33 mg

A levodopa product containing levodopa, registered in Belgium by Merz Therapeutics. The same ATC class is registered in 12 of our 19 countries.

ATC N04BA01

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedInbrija 33 mgATCN04BA01REGISTER NO.BE-AMP-SAM546773-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about levodopaAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Levodopa is registered in 12 of 19 countries.

Countries holding a registration under ATC N04BA01 (levodopa), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search levodopa products by name

Levodopa · ATC N04BA01

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of levodopa costs, country by country.

Normalised to the WHO defined daily dose (3.5 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Levodopa · price per daily dose (3.5 g)

USD · FX 28 Sept 2026

  • ES Spain$465.34
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Levodopa
Manufacturer
Merz Therapeutics
Country
Belgium (BE)
ATC code
N04BA01
ATC class
Levodopa
Defined daily dose
3.5 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

1 priced
  • be_apb
    4938221
    EUR 437.55
  • be_apb
    7748643

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

140 interactions on record for levodopa.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check levodopa against other medicinesHow interaction checks work

Levodopa · interactions on record

140 records

  • 4 severe
  • 122 moderate
  • 14 minor

Most severe, free to view

  • ProcarbazineL01XB01severe
  • OzanimodL04AA38severe
  • OzanimodL04AE02severe
  • Methylthioninium chlorideV03AB17severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Levodopa in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All levodopa products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Inbrija
  • Iceland · Inbrija
  • Liechtenstein · Inbrija
  • Norway · Inbrija

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e1d3d279-2ac5-48c6-9e6c-486356301965
GET /v1/drugs/e1d3d279-2ac5-48c6-9e6c-486356301965?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Inhalation powder, hard capsule",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Inbrija 33 mg",
  "name_fr": "Inbrija 33 mg",
  "name_nl": "Inbrija 33 mg",
  "amp_code": "SAM546773-00",
  "strengths": [
    "42.0000",
    "42.0000",
    "42.0000"
  ],
  "pack_count": 4,
  "substances": [
    "Levodopa",
    "Potassium Chloride",
    "Potassium Hydroxide",
    "Propylene Glycol",
    "Sodium Chloride"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Levodopa",
  "authorisation_numbers": [
    "EU/1/19/1390/001",
    "EU/1/19/1390/002",
    "EU/1/19/1390/003",
    "EU/1/19/1390/004"
  ]
}
API referenceMCP serverPlans

See everything about levodopa.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console